The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors

In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis.

This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from "gene-driven" to "epigenetic-metabolic-driven" early detection.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Malignant Tumors Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Primary Objective To evaluate differential expression of serum histone succinylation between malignant solid tumor patients and healthy controls, thereby validating its early detection value.

Secondary Objectives

To determine correlations between serum histone succinylation levels and:

Tumor types Tumor stages

To statistically analyze associations of serum histone succinylation with:

Therapeutic efficacy (surgical intervention, radiotherapy, systemic therapy) Clinicopathological variables

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Case Group:

Aged ≥18 years, regardless of sex；
Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy；

Control Group:

Aged ≥18 years, regardless of sex；
Non-cancer participants enrolled through health screenings；

Exclusion criteria

Pregnant individuals；
Individuals with serious mental disorders or communication barriers；
Other conditions deemed by investigators to contraindicate study participation；

Treatment and study plan

Primary outcomes

Evaluate the positive rate of serum histone succinylation in patients with malignant solid tumors

Time frame: 2025.08.01-2026.12.31

Evaluate the positive rate of serum histone succinylation in malignant solid tumor patients versus healthy individuals through Western blot analysis, quantify the percentage difference between the two groups, and thereby validate its potential for early cancer screening

Secondary outcomes

Define the relationship between histone succinylation modifications in serum and different tumor types as well as tumor staging

Time frame: 2025.08.01-2026.12.31

Analyze the relationship between histone succinylation modifications in serum and therapeutic efficacy (specifically surgery, radiotherapy, and systemic therapy)。

Study contacts

Contact information is provided by the study sponsor or research team.

Wang Fang Doctor, Graduate Student

CONTACT

[email protected]

18337312280

Sponsors and collaborators

Lead sponsor

Yinghua Ji

Other

Registry information

Official study title

Serum Histone Succinylation: A Predictive Biomarker for Malignant Solid Tumors

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2026
First posted: Aug 20, 2025
Registry last updated: Aug 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting